• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

维莫德吉肌肉痉挛不良事件的纵向有序分类数据分析:不同药代动力学模型的比较

Analysis of Longitudinal-Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models.

作者信息

Lu Tong, Yang Yujie, Jin Jin Y, Kågedal Matts

机构信息

Department of Clinical Pharmacology, Genentech, Inc, South San Francisco, California, USA.

Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The State University of New York, Buffalo, New York, USA.

出版信息

CPT Pharmacometrics Syst Pharmacol. 2020 Feb;9(2):96-105. doi: 10.1002/psp4.12487. Epub 2020 Jan 30.

DOI:10.1002/psp4.12487
PMID:31877239
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7020275/
Abstract

Longitudinal-ordered categorical data, common in clinical trials, can be effectively analyzed with nonlinear mixed effect models. In this article, we systematically evaluated the performance of three different models in longitudinal muscle spasm adverse event (AE) data obtained from a clinical trial for vismodegib: a proportional odds (PO) model, a discrete-time Markov model, and a continuous-time Markov model. All models developed based on weekly spaced data can reasonably capture the proportion of AE grade over time; however, the PO model overpredicted the transition frequency between grades and the cumulative probability of AEs. The influence of data frequency (daily, weekly, or unevenly spaced) was also investigated. The PO model performance reduced with increased data frequency, and the discrete-time Markov model failed to describe unevenly spaced data, but the continuous-time Markov model performed consistently well. Clinical trial simulations were conducted to illustrate the muscle spasm resolution time profile during the 8-week dose interruption period after 12 weeks of continuous treatment.

摘要

纵向有序分类数据在临床试验中很常见,可以用非线性混合效应模型进行有效分析。在本文中,我们系统评估了三种不同模型在从维莫德吉的一项临床试验中获得的纵向肌肉痉挛不良事件(AE)数据中的表现:比例优势(PO)模型、离散时间马尔可夫模型和连续时间马尔可夫模型。所有基于每周间隔数据开发的模型都能合理地捕捉随时间变化的AE等级比例;然而,PO模型高估了等级之间的转换频率和AE的累积概率。还研究了数据频率(每日、每周或间隔不均匀)的影响。PO模型的性能随着数据频率的增加而降低,离散时间马尔可夫模型无法描述间隔不均匀的数据,但连续时间马尔可夫模型始终表现良好。进行了临床试验模拟,以说明在连续治疗12周后的8周剂量中断期内肌肉痉挛缓解时间的情况。

相似文献

1
Analysis of Longitudinal-Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models.维莫德吉肌肉痉挛不良事件的纵向有序分类数据分析:不同药代动力学模型的比较
CPT Pharmacometrics Syst Pharmacol. 2020 Feb;9(2):96-105. doi: 10.1002/psp4.12487. Epub 2020 Jan 30.
2
Efficacy and safety profile of vismodegib in a real-world setting cohort of patients with advanced basal cell carcinoma in Argentina.维莫德吉在阿根廷晚期基底细胞癌真实世界设定队列患者中的疗效和安全性概况。
Int J Dermatol. 2020 May;59(5):627-632. doi: 10.1111/ijd.14780. Epub 2020 Feb 7.
3
Efficacy, rate of tumor response, and safety of a short course (12-24 weeks) of oral vismodegib in various histologic subtypes (infiltrative, nodular, and superficial) of high-risk or locally advanced basal cell carcinoma, in an open-label, prospective case series clinical trial.在一项开放性、前瞻性病例系列临床试验中,评估了短疗程(12-24 周)口服维莫德吉在各种组织学亚型(浸润性、结节性和浅表性)高危或局部晚期基底细胞癌中的疗效、肿瘤缓解率和安全性。
J Am Acad Dermatol. 2020 Apr;82(4):946-954. doi: 10.1016/j.jaad.2019.12.002. Epub 2019 Dec 10.
4
Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.维莫德吉治疗晚期基底细胞癌患者:国际开放标签试验STEVIE的初步分析
Eur J Cancer. 2017 Nov;86:334-348. doi: 10.1016/j.ejca.2017.08.022. Epub 2017 Nov 5.
5
Levocarnitine for vismodegib-associated muscle spasms: a pilot randomized, double-blind, placebo-controlled, investigator-initiated trial.左卡尼汀治疗维莫德吉相关肌肉痉挛:一项由研究者发起的随机、双盲、安慰剂对照试验
J Eur Acad Dermatol Venereol. 2018 Jul;32(7):e298-e299. doi: 10.1111/jdv.14844. Epub 2018 Feb 23.
6
Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. hedgehog 通路抑制剂维莫德吉(GDC-0449)在局部晚期或转移性实体瘤患者中的药代动力学剂量调整研究。
Clin Cancer Res. 2011 Sep 1;17(17):5774-82. doi: 10.1158/1078-0432.CCR-11-0972. Epub 2011 Jul 13.
7
Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.晚期基底细胞癌患者接受 Hedgehog 通路抑制剂维莫德吉治疗的扩大准入研究。
J Am Acad Dermatol. 2014 Jan;70(1):60-9. doi: 10.1016/j.jaad.2013.09.012. Epub 2013 Nov 1.
8
Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma.晚期基底细胞癌患者中刺猬通路抑制剂相关不良事件的特征与管理
Oncologist. 2016 Oct;21(10):1218-1229. doi: 10.1634/theoncologist.2016-0186. Epub 2016 Aug 10.
9
Hepatotoxicity with Vismodegib: An MD Anderson Cancer Center and Research on Adverse Drug Events and Reports Project.维莫德吉的肝毒性:MD安德森癌症中心与药物不良事件及报告项目研究
Drugs R D. 2017 Mar;17(1):211-218. doi: 10.1007/s40268-016-0168-2.
10
A Minimal Continuous-Time Markov Pharmacometric Model.一个最小连续时间 Markov 药效计量学模型。
AAPS J. 2017 Sep;19(5):1424-1435. doi: 10.1208/s12248-017-0109-1. Epub 2017 Jun 20.

引用本文的文献

1
A Novel Two-Part Mixture Model for the Incidence and Time Course of Cytokine Release Syndrome After Elranatamab Dosing in Multiple Myeloma Patients.一种用于多发性骨髓瘤患者接受埃拉纳单抗给药后细胞因子释放综合征发病率和病程的新型两部分混合模型。
Clin Pharmacol Ther. 2025 Jun;117(6):1687-1695. doi: 10.1002/cpt.3533. Epub 2025 Feb 16.
2
Population exposure-response analysis of the effect of ritlecitinib on eyebrow assessment and eyelash assessment in patients with alopecia areata.利特昔替尼对斑秃患者眉毛评估和睫毛评估影响的群体暴露-反应分析。
CPT Pharmacometrics Syst Pharmacol. 2025 Feb;14(2):389-402. doi: 10.1002/psp4.13283. Epub 2025 Jan 15.
3

本文引用的文献

1
Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib.基于阿法替尼的肿瘤学中暴露驱动的不良事件时间过程建模。
CPT Pharmacometrics Syst Pharmacol. 2019 Apr;8(4):230-239. doi: 10.1002/psp4.12384. Epub 2019 Feb 27.
2
A continuous-time multistate Markov model to describe the occurrence and severity of diarrhea events in metastatic breast cancer patients treated with lumretuzumab in combination with pertuzumab and paclitaxel.一种连续时间多状态马尔可夫模型,用于描述接受鲁美替尼单抗联合曲妥珠单抗和紫杉醇治疗的转移性乳腺癌患者腹泻事件的发生和严重程度。
Cancer Chemother Pharmacol. 2018 Sep;82(3):395-406. doi: 10.1007/s00280-018-3621-9. Epub 2018 Jun 18.
3
A tutorial on pharmacometric Markov models.
药物计量马尔可夫模型教程。
CPT Pharmacometrics Syst Pharmacol. 2025 Feb;14(2):197-216. doi: 10.1002/psp4.13278. Epub 2024 Dec 13.
4
Exposure-response modeling for nausea incidence for cotadutide using a Markov modeling approach.采用马尔可夫模型方法对科塔度肽引起恶心发生率的暴露-反应关系进行建模。
CPT Pharmacometrics Syst Pharmacol. 2024 Sep;13(9):1582-1594. doi: 10.1002/psp4.13194. Epub 2024 Jul 23.
5
Longitudinal efficacy and safety modeling and simulation framework to aid dose selection of belantamab mafodotin for patients with multiple myeloma.用于辅助多发性骨髓瘤患者选择贝兰他单抗mafodotin 剂量的纵向疗效和安全性建模与模拟框架。
CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1411-1424. doi: 10.1002/psp4.13016. Epub 2023 Aug 2.
6
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development.肿瘤临床药物开发中建模和模拟实践的全面监管和行业审查。
J Pharmacokinet Pharmacodyn. 2023 Jun;50(3):147-172. doi: 10.1007/s10928-023-09850-2. Epub 2023 Mar 4.
7
Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.采用 Markov 建模方法评估卡培他滨所致手足综合征患者报告的严重程度。
Cancer Chemother Pharmacol. 2020 Sep;86(3):435-444. doi: 10.1007/s00280-020-04128-7. Epub 2020 Aug 27.
A Minimal Continuous-Time Markov Pharmacometric Model.
一个最小连续时间 Markov 药效计量学模型。
AAPS J. 2017 Sep;19(5):1424-1435. doi: 10.1208/s12248-017-0109-1. Epub 2017 Jun 20.
4
Improvement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients.多分类临床终点潜在变量间接反应模型的改进:在银屑病患者中司库奇尤单抗治疗效果建模的应用
J Pharmacokinet Pharmacodyn. 2017 Oct;44(5):437-448. doi: 10.1007/s10928-017-9531-3. Epub 2017 Jun 20.
5
Semi-Mechanism-Based Population Pharmacokinetic Modeling of the Hedgehog Pathway Inhibitor Vismodegib.基于半机制的刺猬通路抑制剂维莫德吉群体药代动力学建模
CPT Pharmacometrics Syst Pharmacol. 2015 Nov;4(11):680-9. doi: 10.1002/psp4.12039. Epub 2015 Nov 9.
6
Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations.开发抗癌药物治疗的暴露/反应模型:特殊考量
CPT Pharmacometrics Syst Pharmacol. 2015 Jan;4(1):e00016. doi: 10.1002/psp4.16. Epub 2015 Jan 21.
7
A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.一项评估维莫德吉在可手术基底细胞癌中的疗效和安全性的 II 期、多中心、开放标签、3 队列试验。
J Am Acad Dermatol. 2015 Jul;73(1):99-105.e1. doi: 10.1016/j.jaad.2015.03.013. Epub 2015 Apr 24.
8
Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol.在接受培塞丽珠治疗的类风湿关节炎患者中,ACR20、ACR50 和 ACR70 改善评分的同时暴露-反应建模。
CPT Pharmacometrics Syst Pharmacol. 2014 Oct 29;3(10):e143. doi: 10.1038/psp.2014.41.
9
Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).磷酸芦可替尼对类风湿关节炎(RA)患者美国风湿病学会20%改善标准(ACR20)疗效的药代动力学-药效学建模以支持剂量选择
J Clin Pharmacol. 2015 Mar;55(3):328-35. doi: 10.1002/jcph.406. Epub 2014 Nov 20.
10
Exposure-response modeling of clinical end points using latent variable indirect response models.使用潜在变量间接响应模型对临床终点进行暴露-反应建模。
CPT Pharmacometrics Syst Pharmacol. 2014 Jun 4;3(6):e117. doi: 10.1038/psp.2014.15.